Gillette looks to lasers
This article was originally published in The Rose Sheet
Executive Summary
Razor marketer signs agreement with laser hair removal research firm Palomar Medical Technologies to develop and "potentially" market a patented home-use, light-based hair removal device for women, the two firms announce Feb. 19. Gillette will pay up to $7 mil. to support product development over 30 months. Marketing laser hair removal products would "augment" Gillette's leading position in the razor category rather than cannibalize its existing business, company says, noting, "If the technology paradigm does shift in 20 years, Gillette wants to be shaping that"...
You may also be interested in...
Palomar, Gillette renegotiate
Firms have extended "launch decision" for a home-use, light-based hair removal device for women until no later than Feb. 29, 2008, according to Dec. 21 release. Palomar Medical Technologies says that under the existing development and license agreement - forged in February 2003 and amended and restated in February 2007 - Gillette was to make the launch decision by Jan. 7 (1"The Rose Sheet" Feb. 24, 2003, In Brief). However, companies have entered into negotiations for a new arrangement expected to include "the release of Palomar from exclusivity," in return for which "there would be a reduction in the percentage of net sales that Gillette pays to Palomar and a change from annual payments...to reduced calendar quarterly payments for a certain period," Palomar expects. There are no assurances that a new definitive agreement will be reached, the firm says, noting that the existing agreement could be terminated. L'Oréal also has been drawn to aesthetic devices; in December, the company announced a partnership with Light BioScience to co-develop stimulation devices for reducing wrinkles via light-emitting-diode photomodulation (2"The Rose Sheet" Dec. 17, 2007, In Brief)
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.